Treatment Trial for Acute Central Serous Chorioretinopathy

NACompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Acute Central Serous Chorioretinopathy
Interventions
DEVICE

577-MPL

All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the

DEVICE

577-TL

"All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-TL arm.~100 microns light spot size, 0.05 seconds duration, 80 \~ 200 milliwatts of power"

Trial Locations (1)

510060

Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Jin Chen-jin

OTHER

NCT02784665 - Treatment Trial for Acute Central Serous Chorioretinopathy | Biotech Hunter | Biotech Hunter